STERIS Plc (STE) has had various analysts discussing its investment risk, possible worth, and its portfolio retention value. The healthcare sentiment surrounding the stock is cautious, and its shareholder return risk is elevated. Many believe the healthcare company is underperforming compared to Nasdaq and Dow. Interestingly, strong revenue growth occurred in Q3 2025 amongst margin challenges, and Jim Cramer has given a buy call, regarding it as a strong company. Current financials show evidence that the market may be underestimating the company.
STERIS has also engaged in strategic acquisitions amidst macro issues, despite underperformance in Q4. Furthermore, a subsidiary reached a $48.15 million settlement in Ethylene Oxide litigation. The company's international revenue and Q3 earnings have met estimates. However, a planned restructuring led to layoffs. The company sold its renal care business for $196 million and acquired Key Surgical for $850 million. Other major changes include a CEO transition, closure of plants in Brazil and England, and addition of a new board member. Despite some losses, the stock outperformed the market, with current price target set at $262.50.
Steris Plc STE News Analytics from Wed, 24 Jun 2015 07:00:00 GMT to Sat, 19 Apr 2025 12:07:07 GMT -
Rating 5
- Innovation 7
- Information 6
- Rumor -3
